Publications by authors named "Jianhai Guo"
Pharmacotherapy is crucial for advanced hepatocellular carcinoma (HCC). The multi-kinase inhibitor donafenib offers superior survival benefits over sorafenib. Donafenib has first-line status, but there is limited research for combination therapies with this anticancer agent.
View Article and Find Full Text PDFPurpose: Recently, hepatic arterial infusion chemotherapy (HAIC) has also gained popularity for hepatocellular carcinoma (HCC). Several studies have compared HAIC and Transarterial chemoembolization (TACE). However, comparisons between TACE plus HAIC and HAIC are rarely reported.
View Article and Find Full Text PDFArticle Synopsis
- This study aimed to identify risk factors for severe hypersensitivity reactions to oxaliplatin (OXA) during hepatic arterial infusion chemotherapy (HAIC) in gastrointestinal cancer patients.
- Out of 84 patients who experienced hypersensitivity, 27.4% had severe reactions, and a study of retreatment showed a recurrence rate of 51.9% for those with non-severe reactions.
- The analysis found that higher doses of OXA significantly increased the risk of severe reactions, highlighting the need for caution with dosing during treatment.
Article Synopsis
- * HAIC using oxaliplatin, fluorouracil, and leucovorin (referred to as HAIC-FOLFOX) has shown better survival rates than standard first-line treatments, but inconsistencies in the HAIC procedure have led to challenges in its safe application.
- * An expert consensus conference held in March 2023 in Guangzhou, China resulted in 22 recommendations that cover the candidate assessment, technical details, outcomes, complications, and management strategies related to HA
Background And Aim: Transarterial chemoembolization combined with hepatic arterial infusion chemotherapy (TACE-HAIC) has shown encouraging efficacy in the treatment of unresectable hepatocellular carcinoma (HCC). We aimed to develop a novel nomogram to predict overall survival (OS) of patients with unresectable HCC treated with TACE-HAIC.
Methods: A total of 591 patients with unresectable HCC treated with TACE-HAIC between May 2009 and September 2020 were enrolled.
Article Synopsis
- - The study aimed to compare the effectiveness and safety of two chemotherapy treatments—HAI of oxaliplatin plus raltitrexed (TOMOX) and HAI of oxaliplatin plus 5-fluorouracil (FOLFOX)—for patients with unresectable colorectal cancer liver metastases (CRCLM).
- - A total of 113 patients were randomly assigned to receive either TOMOX or FOLFOX, with primary endpoints focusing on progression-free survival (PFS) and objective response rate (ORR), while secondary endpoints included overall survival (OS) and adverse events.
- - Results showed no significant difference between the two treatments in terms of PFS (5.8 months for
Background: Hepatic arterial infusion chemotherapy delivers the drug directly to the liver. We aim to explore the benefits and tolerability of Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal liver metastasis refractory to standard systemic chemotherapy.
Methods: This study analyzed 47 patients treated with hepatic arterial infusion chemotherapy plus regorafenib after standard systemic oxaliplatin and/or irinotecan in combination with bevacizumab or cetuximab between Jan 2017 and Jun 2020.
Article Synopsis
- The study examined the effectiveness and safety of combining hepatic artery infusion chemotherapy (HAIC) with anti-PD-1 immunotherapy and tyrosine kinase inhibitors (TKIs) in treating advanced hepatocellular carcinoma (HCC).
- A total of 27 patients were analyzed, with a median follow-up of 12.9 months, showing a median progression-free survival of 10.6 months, an objective response rate of 63.0%, and a disease control rate of 92.6%.
- No patients experienced treatment-related deaths, indicating that the combined therapy was both effective and safe for advanced HCC.
Article Synopsis
- A clinical trial assessed the effectiveness and safety of I-labeled metuximab in combination with transcatheter arterial chemoembolization (TACE) for treating patients with unresectable hepatocellular carcinoma.
- Results showed that patients receiving TACE along with I-metuximab experienced a median time to tumor recurrence of 6 months compared to 3 months for those receiving TACE alone.
- Additionally, the combined treatment led to a median overall survival of 28 months versus 19 months for TACE alone, demonstrating better outcomes and good patient tolerance for the new treatment.
Article Synopsis
- Patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) generally have poor survival rates, but this study explored how combining conventional transarterial chemoembolization (cTACE) with hepatic arterial infusion chemotherapy (HAIC) affects outcomes.
- In a retrospective evaluation of 155 patients, those receiving the combination treatment (cTACE-HAIC) showed significantly longer overall survival (9 months) and progression-free survival (6 months) compared to those who received cTACE alone (5 months and 2 months, respectively).
- The study concluded that cTACE-HAIC is associated with better survival outcomes without increasing severe treatment-related side effects compared to cTACE alone.
Purpose: To evaluate the prognostic value of pretreatment serum γ-glutamyltransferase (GGT) level in patients with advanced hepatocellular carcinoma (HCC) receiving transarterial chemoembolization.
Materials And Methods: This retrospective study included 140 patients (123 male, 17 female; mean age, 56.9 y ± 12.
Article Synopsis
- TACE and HAIC are treatments for advanced hepatocellular carcinoma (HCC) that show local effectiveness, and S-1 is an oral chemotherapy that works against advanced HCC.
- This study aimed to evaluate the safety and effectiveness of combining TACE and HAIC with or without S-1 in patients with advanced HCC.
- Results showed no significant improvement in tumor response rates or survival outcomes when S-1 was added, and both treatment approaches had similar safety profiles.
Article Synopsis
- The study examines the effectiveness and safety of combining sorafenib with hepatic arterial infusion chemotherapy (HAIC) after transarterial chemoembolization (TACE) for patients with intermediate and advanced hepatocellular carcinoma (HCC).
- Conducted as a phase II trial, sixty-six participants were treated with sorafenib followed by intra-arterial administration of chemotherapy agents, with safety and progression-free survival as key outcomes.
- Results showed an objective response rate of 42.4% and a disease control rate of 87.9%, though some patients experienced significant toxicity, including grade 3-4 side effects like thrombocytopenia.
The purpose of this study was to assess the safety, technical results, and clinical outcomes of CT-guided percutaneous microwave ablation of category T1a renal cell carcinoma. This retrospective study investigated consecutive patients who underwent CT-guided microwave ablation for T1a renal cell carcinoma from October 2015 to May 2019. Patient demographics including tumor characteristics, comorbidities, technical details, and clinical outcomes were evaluated.
View Article and Find Full Text PDFTo report on the safety, technical results, and oncologic outcomes of computed tomography guided percutaneous microwave ablation of stage cT1b renal cell carcinoma. This single-center retrospective study investigated consecutive patients with T1b renal cell carcinoma who were treated with CT guided percutaneous microwave ablation between December 2015 and May 2019. Patient baseline characteristics, tumor biologic features, technical parameters, clinical outcomes, and complications were recorded and evaluated.
View Article and Find Full Text PDFAims: This study aims to observe the preliminary clinical efficacy of percutaneous interstitial brachytherapy using iodine-125 seeds for the treatment of advanced malignant lung tumors.
Subjects And Methods: This retrospective study enrolled 24 patients in our hospital with advanced malignant lung tumors between June 2013 and November 2017. Computed tomography (CT)-guided iodine-125 seed implantation therapy was administered to these patients.
Objective: To investigate the safety, efficacy, and prognostic factors of hepatic arterial infusion chemotherapy (HAIC) with raltitrexed and oxaliplatin post-transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC).
Methods: Thirty-seven patients with uHCC who received HAIC with raltitrexed and oxaliplatin post-TACE between June 2014 and December 2016 at our hospital were recruited. The primary endpoint was overall survival (OS), and secondary endpoint was progression-free survival (PFS).
Article Synopsis
- - The study aims to compare the survival outcomes of patients with right-sided primary (RSP) tumors versus left-sided primary (LSP) tumors undergoing hepatic arterial infusion chemotherapy (HAIC) for metastatic colorectal cancer.
- - A total of 168 patients were analyzed, revealing similar response rates and disease control rates for both tumor sides; median overall survival was 16.3 months for LSP patients and 9.3 months for RSP patients.
- - The results show no significant survival difference between LSP and RSP patients post-treatment, indicating a need for further research to confirm these observations.
Article Synopsis
- The study aimed to evaluate the effectiveness of trefoil factor family 3 (TFF3) as a biomarker for the early detection of colorectal cancer (CC).
- Researchers tested serum levels of TFF3 and carcino-embryonic antigen (CEA) in 527 participants, including healthy individuals and patients with colorectal adenoma and cancer.
- The findings indicated that TFF3 levels were significantly higher in CC patients compared to controls and suggested that a combined model of TFF3 and CEA could improve diagnostic accuracy significantly over using CEA alone.
Objective: To investigate the prognostic factors in chemorefractory colorectal cancer liver metastasis (CRCLM) patients treated by transarterial chemoembolization (TACE) and sustained hepatic arterial infusion chemotherapy (HAIC).
Methods: Between 2006 and 2015, 162 patients who underwent 763 TACE and HAIC in total were enrolled in this retrospective study, including 110 males and 52 females, with a median age of 60 (range, 26-83) years. Prognostic factors were assessed with Log-rank test, Cox univariate and multivariate analyses.
Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis.
World J Gastroenterol
February 2017
Article Synopsis
- The study aimed to assess the effectiveness and safety of two types of chemotherapy (raltitrexed versus 5-fluorouracil) delivered through hepatic artery infusion for treating liver metastases from colorectal cancer in patients who didn't respond to previous treatments.
- A total of 42 patients were analyzed, with 24 receiving 5-fluorouracil and 18 receiving raltitrexed; results indicated no significant survival difference between the two treatment groups, with median survival times of 20.6 months for raltitrexed and 15.4 months for 5-fluorouracil after starting HAIC.
- Side effects varied, with more cases of leuk
Colorectal cancer liver metastasis (CRLM) is a refractory disease after failure of first-line or second-line chemotherapy. Bevacizumab is recommended as first-line therapy for advanced colorectal cancer, but is unproven in CRLM through the hepatic artery. We report favorable outcomes with targeted vessel regional chemotherapy (TVRC) for liver metastatic gastric cancer.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare the effectiveness and safety of chemoembolization alone versus chemoembolization combined with hepatic arterial infusion chemotherapy (HAIC) using oxaliplatin, 5-fluorouracil, and folinic acid for patients with inoperable hepatocellular carcinoma (HCC).
- A total of 84 inoperable HCC patients participated, with 39 receiving only chemoembolization and 45 receiving the combined treatment; they evaluated progression-free survival, objective response rates, disease control rates, and adverse effects.
- Results indicated that the combination treatment showed improved objective response rates and median progression-free survival compared to chemoembolization alone, though it also led to increased pain levels, but for advanced-stage
Objective: Transcatheter arterial chemoembolization (TACE) is a standard treatment for hepatocellular carcinoma (HCC) and/or some unresectable liver metastasis tumors. Hypervascular liver metastatic lesions such as metastasis from gastrointestinal stromal tumor (GIST) are an indication for transcatheter arterial embolization (TAE). The purpose of this study was to evaluate the efficacy and safety of Embosphere(®)-TAE (Embo-TAE) in comparison with conventional TACE (cTACE) for the treatment of liver metastasis from GIST.
View Article and Find Full Text PDFArticle Synopsis
- This study assesses the effectiveness and safety of combining regional chemotherapy via the hepatic artery with transarterial embolization in advanced gastric cancer patients who have liver metastases, particularly after unsuccessful prior treatments.
- A total of 22 patients received a median of 7 treatments, showing a median time-to-progression of about 6 months and a median overall survival of nearly 19 months following the diagnosis of liver metastasis.
- The combination therapy led to a reduced overall chemotherapy dosage, fewer side effects, and improved quality of life for the patients, suggesting its potential as a salvage treatment option.